Jyong Biotech
MENS
2 hedge funds and large institutions have $781K invested in Jyong Biotech in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.12% more ownership
Funds ownership: 0% → 0.12% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$609K |
| 2 |
HF
HRT Financial
New York
|
+$197K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $591K | +$609K | +70,970 | New |
|
|
HF
2
HRT Financial
New York
| $190K | +$197K | +22,922 | New |
|
MENS Hedge Fund Activity: Q2 2025 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q2 2025, worth a combined $781K.
Buyers outnumbered sellers: 2 funds opened new MENS positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $609K.
- 2 institutional investors held Jyong Biotech (MENS) as of Q2 2025, up from 0 in Q1 2025.
- Funds reported $781K of Jyong Biotech stock for Q2 2025.
- 2 funds opened new Jyong Biotech positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest Jyong Biotech buyer in Q2 2025 was Citadel Advisors, an estimated $609K added.
Based on aggregated 13F filings for Q2 2025.